Targeted therapy is to design corresponding therapeutic drugs for the identified cancer-causing site (the site can be a protein molecule inside the tumor cell or a gene fragment) at the cellular molecular level, and the drug enters the body It will specifically select oncogenic sites to combine and act, so that tumor cells will die specifically, without affecting normal tissue cells around the tumor.

The global Targeted Drugs for Colorectal Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Colorectal Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Colorectal Cancer.

Report Scope

The Targeted Drugs for Colorectal Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Colorectal Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Targeted Drugs for Colorectal Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Targeted Drugs for Colorectal Cancer Market Report

Report Metric	Details
Report Name	Targeted Drugs for Colorectal Cancer Market
CAGR	5%
Segment by Type	EGFR Target BRAF Target MEK1/2 Targets BRAF V600 Target HER2 Target VEGFR-1/2/3 Targets PD-1 Target CTLA-4 Target
Segment by Application	Hospital Specialty Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck, Amgen, F. Hoffmann-La Roche Ltd, Novartis, Array BioPharma, Genentech, Bayer, Sanofi, Lilly, Bristol myers squibb, MSD lreland, HUTCHMED
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Targeted Drugs for Colorectal Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Targeted Drugs for Colorectal Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Colorectal Cancer Market report?

Ans: The main players in the Targeted Drugs for Colorectal Cancer Market are Merck, Amgen, F. Hoffmann-La Roche Ltd, Novartis, Array BioPharma, Genentech, Bayer, Sanofi, Lilly, Bristol myers squibb, MSD lreland, HUTCHMED

What are the Application segmentation covered in the Targeted Drugs for Colorectal Cancer Market report?

Ans: The Applications covered in the Targeted Drugs for Colorectal Cancer Market report are Hospital, Specialty Clinic

What are the Type segmentation covered in the Targeted Drugs for Colorectal Cancer Market report?

Ans: The Types covered in the Targeted Drugs for Colorectal Cancer Market report are EGFR Target, BRAF Target, MEK1/2 Targets, BRAF V600 Target, HER2 Target, VEGFR-1/2/3 Targets, PD-1 Target, CTLA-4 Target

1 Targeted Drugs for Colorectal Cancer Market Overview

1.1 Product Overview and Scope of Targeted Drugs for Colorectal Cancer

1.2 Targeted Drugs for Colorectal Cancer Segment by Type

1.2.1 Global Targeted Drugs for Colorectal Cancer Market Value Comparison by Type (2024-2030)

1.2.2 EGFR Target

1.2.3 BRAF Target

1.2.4 MEK1/2 Targets

1.2.5 BRAF V600 Target

1.2.6 HER2 Target

1.2.7 VEGFR-1/2/3 Targets

1.2.8 PD-1 Target

1.2.9 CTLA-4 Target

1.3 Targeted Drugs for Colorectal Cancer Segment by Application

1.3.1 Global Targeted Drugs for Colorectal Cancer Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Specialty Clinic

1.4 Global Targeted Drugs for Colorectal Cancer Market Size Estimates and Forecasts

1.4.1 Global Targeted Drugs for Colorectal Cancer Revenue 2019-2030

1.4.2 Global Targeted Drugs for Colorectal Cancer Sales 2019-2030

1.4.3 Global Targeted Drugs for Colorectal Cancer Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Targeted Drugs for Colorectal Cancer Market Competition by Manufacturers

2.1 Global Targeted Drugs for Colorectal Cancer Sales Market Share by Manufacturers (2019-2024)

2.2 Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Targeted Drugs for Colorectal Cancer Average Price by Manufacturers (2019-2024)

2.4 Global Targeted Drugs for Colorectal Cancer Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Targeted Drugs for Colorectal Cancer, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Targeted Drugs for Colorectal Cancer, Product Type & Application

2.7 Targeted Drugs for Colorectal Cancer Market Competitive Situation and Trends

2.7.1 Targeted Drugs for Colorectal Cancer Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Targeted Drugs for Colorectal Cancer Players Market Share by Revenue

2.7.3 Global Targeted Drugs for Colorectal Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Targeted Drugs for Colorectal Cancer Retrospective Market Scenario by Region

3.1 Global Targeted Drugs for Colorectal Cancer Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Targeted Drugs for Colorectal Cancer Global Targeted Drugs for Colorectal Cancer Sales by Region: 2019-2030

3.2.1 Global Targeted Drugs for Colorectal Cancer Sales by Region: 2019-2024

3.2.2 Global Targeted Drugs for Colorectal Cancer Sales by Region: 2025-2030

3.3 Global Targeted Drugs for Colorectal Cancer Global Targeted Drugs for Colorectal Cancer Revenue by Region: 2019-2030

3.3.1 Global Targeted Drugs for Colorectal Cancer Revenue by Region: 2019-2024

3.3.2 Global Targeted Drugs for Colorectal Cancer Revenue by Region: 2025-2030

3.4 North America Targeted Drugs for Colorectal Cancer Market Facts & Figures by Country

3.4.1 North America Targeted Drugs for Colorectal Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Targeted Drugs for Colorectal Cancer Sales by Country (2019-2030)

3.4.3 North America Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Targeted Drugs for Colorectal Cancer Market Facts & Figures by Country

3.5.1 Europe Targeted Drugs for Colorectal Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Targeted Drugs for Colorectal Cancer Sales by Country (2019-2030)

3.5.3 Europe Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Targeted Drugs for Colorectal Cancer Market Facts & Figures by Country

3.6.1 Asia Pacific Targeted Drugs for Colorectal Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Targeted Drugs for Colorectal Cancer Sales by Country (2019-2030)

3.6.3 Asia Pacific Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Targeted Drugs for Colorectal Cancer Market Facts & Figures by Country

3.7.1 Latin America Targeted Drugs for Colorectal Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Targeted Drugs for Colorectal Cancer Sales by Country (2019-2030)

3.7.3 Latin America Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Targeted Drugs for Colorectal Cancer Market Facts & Figures by Country

3.8.1 Middle East and Africa Targeted Drugs for Colorectal Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Targeted Drugs for Colorectal Cancer Sales by Country (2019-2030)

3.8.3 Middle East and Africa Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Targeted Drugs for Colorectal Cancer Sales by Type (2019-2030)

4.1.1 Global Targeted Drugs for Colorectal Cancer Sales by Type (2019-2024)

4.1.2 Global Targeted Drugs for Colorectal Cancer Sales by Type (2025-2030)

4.1.3 Global Targeted Drugs for Colorectal Cancer Sales Market Share by Type (2019-2030)

4.2 Global Targeted Drugs for Colorectal Cancer Revenue by Type (2019-2030)

4.2.1 Global Targeted Drugs for Colorectal Cancer Revenue by Type (2019-2024)

4.2.2 Global Targeted Drugs for Colorectal Cancer Revenue by Type (2025-2030)

4.2.3 Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Type (2019-2030)

4.3 Global Targeted Drugs for Colorectal Cancer Price by Type (2019-2030)

5 Segment by Application

5.1 Global Targeted Drugs for Colorectal Cancer Sales by Application (2019-2030)

5.1.1 Global Targeted Drugs for Colorectal Cancer Sales by Application (2019-2024)

5.1.2 Global Targeted Drugs for Colorectal Cancer Sales by Application (2025-2030)

5.1.3 Global Targeted Drugs for Colorectal Cancer Sales Market Share by Application (2019-2030)

5.2 Global Targeted Drugs for Colorectal Cancer Revenue by Application (2019-2030)

5.2.1 Global Targeted Drugs for Colorectal Cancer Revenue by Application (2019-2024)

5.2.2 Global Targeted Drugs for Colorectal Cancer Revenue by Application (2025-2030)

5.2.3 Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Application (2019-2030)

5.3 Global Targeted Drugs for Colorectal Cancer Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Merck

6.1.1 Merck Corporation Information

6.1.2 Merck Description and Business Overview

6.1.3 Merck Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Merck Targeted Drugs for Colorectal Cancer Product Portfolio

6.1.5 Merck Recent Developments/Updates

6.2 Amgen

6.2.1 Amgen Corporation Information

6.2.2 Amgen Description and Business Overview

6.2.3 Amgen Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Amgen Targeted Drugs for Colorectal Cancer Product Portfolio

6.2.5 Amgen Recent Developments/Updates

6.3 F. Hoffmann-La Roche Ltd

6.3.1 F. Hoffmann-La Roche Ltd Corporation Information

6.3.2 F. Hoffmann-La Roche Ltd Description and Business Overview

6.3.3 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.3.4 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product Portfolio

6.3.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

6.4 Novartis

6.4.1 Novartis Corporation Information

6.4.2 Novartis Description and Business Overview

6.4.3 Novartis Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Novartis Targeted Drugs for Colorectal Cancer Product Portfolio

6.4.5 Novartis Recent Developments/Updates

6.5 Array BioPharma

6.5.1 Array BioPharma Corporation Information

6.5.2 Array BioPharma Description and Business Overview

6.5.3 Array BioPharma Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Array BioPharma Targeted Drugs for Colorectal Cancer Product Portfolio

6.5.5 Array BioPharma Recent Developments/Updates

6.6 Genentech

6.6.1 Genentech Corporation Information

6.6.2 Genentech Description and Business Overview

6.6.3 Genentech Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Genentech Targeted Drugs for Colorectal Cancer Product Portfolio

6.6.5 Genentech Recent Developments/Updates

6.7 Bayer

6.6.1 Bayer Corporation Information

6.6.2 Bayer Description and Business Overview

6.6.3 Bayer Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Bayer Targeted Drugs for Colorectal Cancer Product Portfolio

6.7.5 Bayer Recent Developments/Updates

6.8 Sanofi

6.8.1 Sanofi Corporation Information

6.8.2 Sanofi Description and Business Overview

6.8.3 Sanofi Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Sanofi Targeted Drugs for Colorectal Cancer Product Portfolio

6.8.5 Sanofi Recent Developments/Updates

6.9 Lilly

6.9.1 Lilly Corporation Information

6.9.2 Lilly Description and Business Overview

6.9.3 Lilly Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Lilly Targeted Drugs for Colorectal Cancer Product Portfolio

6.9.5 Lilly Recent Developments/Updates

6.10 Bristol myers squibb

6.10.1 Bristol myers squibb Corporation Information

6.10.2 Bristol myers squibb Description and Business Overview

6.10.3 Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Bristol myers squibb Targeted Drugs for Colorectal Cancer Product Portfolio

6.10.5 Bristol myers squibb Recent Developments/Updates

6.11 MSD lreland

6.11.1 MSD lreland Corporation Information

6.11.2 MSD lreland Targeted Drugs for Colorectal Cancer Description and Business Overview

6.11.3 MSD lreland Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.11.4 MSD lreland Targeted Drugs for Colorectal Cancer Product Portfolio

6.11.5 MSD lreland Recent Developments/Updates

6.12 HUTCHMED

6.12.1 HUTCHMED Corporation Information

6.12.2 HUTCHMED Targeted Drugs for Colorectal Cancer Description and Business Overview

6.12.3 HUTCHMED Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)

6.12.4 HUTCHMED Targeted Drugs for Colorectal Cancer Product Portfolio

6.12.5 HUTCHMED Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Targeted Drugs for Colorectal Cancer Industry Chain Analysis

7.2 Targeted Drugs for Colorectal Cancer Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Targeted Drugs for Colorectal Cancer Production Mode & Process

7.4 Targeted Drugs for Colorectal Cancer Sales and Marketing

7.4.1 Targeted Drugs for Colorectal Cancer Sales Channels

7.4.2 Targeted Drugs for Colorectal Cancer Distributors

7.5 Targeted Drugs for Colorectal Cancer Customers

8 Targeted Drugs for Colorectal Cancer Market Dynamics

8.1 Targeted Drugs for Colorectal Cancer Industry Trends

8.2 Targeted Drugs for Colorectal Cancer Market Drivers

8.3 Targeted Drugs for Colorectal Cancer Market Challenges

8.4 Targeted Drugs for Colorectal Cancer Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merck

Amgen Inc

F Hoffmann La Roche Ltd

List of Tables

Table 1. Global Targeted Drugs for Colorectal Cancer Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Targeted Drugs for Colorectal Cancer Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Targeted Drugs for Colorectal Cancer Market Competitive Situation by Manufacturers in 2023

Table 4. Global Targeted Drugs for Colorectal Cancer Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Targeted Drugs for Colorectal Cancer Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Targeted Drugs for Colorectal Cancer Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Targeted Drugs for Colorectal Cancer Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Targeted Drugs for Colorectal Cancer, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Targeted Drugs for Colorectal Cancer, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Targeted Drugs for Colorectal Cancer, Product Type & Application

Table 12. Global Key Manufacturers of Targeted Drugs for Colorectal Cancer, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Targeted Drugs for Colorectal Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Colorectal Cancer as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Targeted Drugs for Colorectal Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Targeted Drugs for Colorectal Cancer Sales by Region (2019-2024) & (K Units)

Table 18. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Region (2019-2024)

Table 19. Global Targeted Drugs for Colorectal Cancer Sales by Region (2025-2030) & (K Units)

Table 20. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Region (2025-2030)

Table 21. Global Targeted Drugs for Colorectal Cancer Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Region (2019-2024)

Table 23. Global Targeted Drugs for Colorectal Cancer Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Region (2025-2030)

Table 25. North America Targeted Drugs for Colorectal Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Targeted Drugs for Colorectal Cancer Sales by Country (2019-2024) & (K Units)

Table 27. North America Targeted Drugs for Colorectal Cancer Sales by Country (2025-2030) & (K Units)

Table 28. North America Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Targeted Drugs for Colorectal Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Targeted Drugs for Colorectal Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Targeted Drugs for Colorectal Cancer Sales by Country (2019-2024) & (K Units)

Table 32. Europe Targeted Drugs for Colorectal Cancer Sales by Country (2025-2030) & (K Units)

Table 33. Europe Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Targeted Drugs for Colorectal Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Targeted Drugs for Colorectal Cancer Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Targeted Drugs for Colorectal Cancer Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Targeted Drugs for Colorectal Cancer Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Targeted Drugs for Colorectal Cancer Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Targeted Drugs for Colorectal Cancer Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Targeted Drugs for Colorectal Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Targeted Drugs for Colorectal Cancer Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Targeted Drugs for Colorectal Cancer Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Targeted Drugs for Colorectal Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Targeted Drugs for Colorectal Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Targeted Drugs for Colorectal Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Targeted Drugs for Colorectal Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Targeted Drugs for Colorectal Cancer Sales (K Units) by Type (2019-2024)

Table 51. Global Targeted Drugs for Colorectal Cancer Sales (K Units) by Type (2025-2030)

Table 52. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Type (2019-2024)

Table 53. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Type (2025-2030)

Table 54. Global Targeted Drugs for Colorectal Cancer Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Targeted Drugs for Colorectal Cancer Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Type (2019-2024)

Table 57. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Type (2025-2030)

Table 58. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Type (2019-2024)

Table 59. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Type (2025-2030)

Table 60. Global Targeted Drugs for Colorectal Cancer Sales (K Units) by Application (2019-2024)

Table 61. Global Targeted Drugs for Colorectal Cancer Sales (K Units) by Application (2025-2030)

Table 62. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Application (2019-2024)

Table 63. Global Targeted Drugs for Colorectal Cancer Sales Market Share by Application (2025-2030)

Table 64. Global Targeted Drugs for Colorectal Cancer Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Targeted Drugs for Colorectal Cancer Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Application (2019-2024)

Table 67. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Application (2025-2030)

Table 68. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Application (2019-2024)

Table 69. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Application (2025-2030)

Table 70. Merck Corporation Information

Table 71. Merck Description and Business Overview

Table 72. Merck Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Merck Targeted Drugs for Colorectal Cancer Product

Table 74. Merck Recent Developments/Updates

Table 75. Amgen Corporation Information

Table 76. Amgen Description and Business Overview

Table 77. Amgen Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Amgen Targeted Drugs for Colorectal Cancer Product

Table 79. Amgen Recent Developments/Updates

Table 80. F. Hoffmann-La Roche Ltd Corporation Information

Table 81. F. Hoffmann-La Roche Ltd Description and Business Overview

Table 82. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product

Table 84. F. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 85. Novartis Corporation Information

Table 86. Novartis Description and Business Overview

Table 87. Novartis Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Novartis Targeted Drugs for Colorectal Cancer Product

Table 89. Novartis Recent Developments/Updates

Table 90. Array BioPharma Corporation Information

Table 91. Array BioPharma Description and Business Overview

Table 92. Array BioPharma Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Array BioPharma Targeted Drugs for Colorectal Cancer Product

Table 94. Array BioPharma Recent Developments/Updates

Table 95. Genentech Corporation Information

Table 96. Genentech Description and Business Overview

Table 97. Genentech Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Genentech Targeted Drugs for Colorectal Cancer Product

Table 99. Genentech Recent Developments/Updates

Table 100. Bayer Corporation Information

Table 101. Bayer Description and Business Overview

Table 102. Bayer Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Bayer Targeted Drugs for Colorectal Cancer Product

Table 104. Bayer Recent Developments/Updates

Table 105. Sanofi Corporation Information

Table 106. Sanofi Description and Business Overview

Table 107. Sanofi Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Sanofi Targeted Drugs for Colorectal Cancer Product

Table 109. Sanofi Recent Developments/Updates

Table 110. Lilly Corporation Information

Table 111. Lilly Description and Business Overview

Table 112. Lilly Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Lilly Targeted Drugs for Colorectal Cancer Product

Table 114. Lilly Recent Developments/Updates

Table 115. Bristol myers squibb Corporation Information

Table 116. Bristol myers squibb Description and Business Overview

Table 117. Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Bristol myers squibb Targeted Drugs for Colorectal Cancer Product

Table 119. Bristol myers squibb Recent Developments/Updates

Table 120. MSD lreland Corporation Information

Table 121. MSD lreland Description and Business Overview

Table 122. MSD lreland Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. MSD lreland Targeted Drugs for Colorectal Cancer Product

Table 124. MSD lreland Recent Developments/Updates

Table 125. HUTCHMED Corporation Information

Table 126. HUTCHMED Description and Business Overview

Table 127. HUTCHMED Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. HUTCHMED Targeted Drugs for Colorectal Cancer Product

Table 129. HUTCHMED Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Targeted Drugs for Colorectal Cancer Distributors List

Table 133. Targeted Drugs for Colorectal Cancer Customers List

Table 134. Targeted Drugs for Colorectal Cancer Market Trends

Table 135. Targeted Drugs for Colorectal Cancer Market Drivers

Table 136. Targeted Drugs for Colorectal Cancer Market Challenges

Table 137. Targeted Drugs for Colorectal Cancer Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Targeted Drugs for Colorectal Cancer

Figure 2. Global Targeted Drugs for Colorectal Cancer Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Targeted Drugs for Colorectal Cancer Market Share by Type in 2023 & 2030

Figure 4. EGFR Target Product Picture

Figure 5. BRAF Target Product Picture

Figure 6. MEK1/2 Targets Product Picture

Figure 7. BRAF V600 Target Product Picture

Figure 8. HER2 Target Product Picture

Figure 9. VEGFR-1/2/3 Targets Product Picture

Figure 10. PD-1 Target Product Picture

Figure 11. CTLA-4 Target Product Picture

Figure 12. Global Targeted Drugs for Colorectal Cancer Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 13. Global Targeted Drugs for Colorectal Cancer Market Share by Application in 2023 & 2030

Figure 14. Hospital

Figure 15. Specialty Clinic

Figure 16. Global Targeted Drugs for Colorectal Cancer Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Targeted Drugs for Colorectal Cancer Market Size (2019-2030) & (US$ Million)

Figure 18. Global Targeted Drugs for Colorectal Cancer Sales (2019-2030) & (K Units)

Figure 19. Global Targeted Drugs for Colorectal Cancer Average Price (US$/Unit) & (2019-2030)

Figure 20. Targeted Drugs for Colorectal Cancer Report Years Considered

Figure 21. Targeted Drugs for Colorectal Cancer Sales Share by Manufacturers in 2023

Figure 22. Global Targeted Drugs for Colorectal Cancer Revenue Share by Manufacturers in 2023

Figure 23. The Global 5 and 10 Largest Targeted Drugs for Colorectal Cancer Players: Market Share by Revenue in 2023

Figure 24. Targeted Drugs for Colorectal Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 25. Global Targeted Drugs for Colorectal Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 26. North America Targeted Drugs for Colorectal Cancer Sales Market Share by Country (2019-2030)

Figure 27. North America Targeted Drugs for Colorectal Cancer Revenue Market Share by Country (2019-2030)

Figure 28. United States Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Canada Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Europe Targeted Drugs for Colorectal Cancer Sales Market Share by Country (2019-2030)

Figure 31. Europe Targeted Drugs for Colorectal Cancer Revenue Market Share by Country (2019-2030)

Figure 32. Germany Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. France Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. U.K. Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Italy Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Russia Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Asia Pacific Targeted Drugs for Colorectal Cancer Sales Market Share by Region (2019-2030)

Figure 38. Asia Pacific Targeted Drugs for Colorectal Cancer Revenue Market Share by Region (2019-2030)

Figure 39. China Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Japan Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. South Korea Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. India Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Australia Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. China Taiwan Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Latin America Targeted Drugs for Colorectal Cancer Sales Market Share by Country (2019-2030)

Figure 47. Latin America Targeted Drugs for Colorectal Cancer Revenue Market Share by Country (2019-2030)

Figure 48. Mexico Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Brazil Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Argentina Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Market Share by Country (2019-2030)

Figure 52. Middle East & Africa Targeted Drugs for Colorectal Cancer Revenue Market Share by Country (2019-2030)

Figure 53. Turkey Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. UAE Targeted Drugs for Colorectal Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Global Sales Market Share of Targeted Drugs for Colorectal Cancer by Type (2019-2030)

Figure 57. Global Revenue Market Share of Targeted Drugs for Colorectal Cancer by Type (2019-2030)

Figure 58. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Type (2019-2030)

Figure 59. Global Sales Market Share of Targeted Drugs for Colorectal Cancer by Application (2019-2030)

Figure 60. Global Revenue Market Share of Targeted Drugs for Colorectal Cancer by Application (2019-2030)

Figure 61. Global Targeted Drugs for Colorectal Cancer Price (US$/Unit) by Application (2019-2030)

Figure 62. Targeted Drugs for Colorectal Cancer Value Chain

Figure 63. Targeted Drugs for Colorectal Cancer Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Distributors Profiles

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions